Search results :

Olmesartan

More information: STITCH, PubChem and possibly Wikipedia

ATC Codes: None found

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8
Influenza-like symptoms common, 3% - 3.59% 3.24% x x x x x x x x
Dizziness common, 0% - 3.08% 0% - 3.57% x x x x x x x x
Headache postmarketing — 0% - 7.53% 0% - 8.65% x x x x x x x x
Abdominal pain postmarketing, common x x x x x x x x
Haematuria common, 1.52% - 2.65% 1.8% x x x x x x x x
Bronchitis common, 0.404% - 5.05% 1.8% - 4.29% x x x x x x x x
Influenza like illness 1.35% - 2.14% 1.93% x
Hypertriglyceridaemia uncommon, 2.05% - 2.12% 1.08% x x x x x x x x
Hyperglycaemia common, 0.947% - 2.56% 2.52% x x x x x x x x
Upper respiratory tract infection 0% - 3.59% 0% - 4.68% x x
Nasopharyngitis 0% - 2.46% 0% - 7.14% x x
Gamma-glutamyltransferase increased 0.676% - 2.84% 1.72% - 1.98% x x
Pharyngitis common, 0% - 2.15% 0% - 1.08% x x x x x x x x
Sinusitis common, 0.901% - 1.45% 2.16% - 3.22% x x x x x x x x
Urinary tract infection common, 0% - 1.75% 0.644% - 0.721% x x
Fatigue postmarketing — 0% - 1.41% 0.901% - 1.07% x x
Pain in extremity 0.47% - 1.16% 1.5% x
Pain common, 0.568% - 1.54% 0.541% x x
Back pain common, 0.216% - 4.04% 1.44% - 1.72% x x x x x x x x
Cough postmarketing — 0.225% - 4.3% 0% - 3.57% x x x x x x x x
Rhinitis common, 0% - 3.45% 0% - 1.85% x x x x x x x x
Vertigo uncommon, 1.05% - 1.28% 0.858% x x x x x x x x
Diarrhoea common, 0% - 1.86% 0% - 3.57% x x x x x x x x
Arthralgia 0% - 1.97% 0.721% - 1.5% x x x x x x x x
Bone pain common, 0.513% - 1.06% 0.541% x x
Alanine aminotransferase increased 0.676% - 1.7% 0.858% - 1.62% x x
Chest pain common, 0.379% - 1.05% 0.541% - 0.858% x x x x x x x x
Blood uric acid increased 0.386% - 1.32% 1.29% x
Blood glucose increased 0.632% - 1.13% 2.58% x
Dyspepsia common, 0.189% - 1.26% 1.08% - 1.29% x x x x x x x x
Acute bronchitis 0.431% - 2.02% x x
Gastroenteritis common, 0% - 1.59% 0% - 0.644% x x x x x x x x
Influenza 0% - 3.77% 0% - 3.57% x x
Arthritis common, 0% - 1.03% 0.18% x x x x x x x x
Hyperuricaemia uncommon, 0% - 1.77% 0.901% x x x x x x x x
Inflicted injury 0.513% - 1.33% 0.541% x
Insomnia 0.189% - 1.59% 1.44% - 1.93% x x
Aspartate aminotransferase increased 0% - 1.7% 0.858% - 1.08% x x
Angina pectoris uncommon x x
Eczema uncommon x
Rash postmarketing, uncommon x x x x x x x x
Hypercholesterolaemia uncommon x x x x x x x
Hyperlipidaemia uncommon x x x
Orthostatic hypotension uncommon x
Palpitations uncommon x
Syncope uncommon x
Tachycardia uncommon x x x x x x x x
Blood potassium increased uncommon x
Toothache 0.189% - 1.54% 0.36% x
Oedema peripheral common, 0.379% - 1.19% 0.721% - 1.29% x x x x x x x x
Creatine phosphokinase increased 0.379% - 1.59% 0.721% x x x x x x x
Spinal disorder 0.47% - 0.901% 1.5% x
Nausea postmarketing, 0.189% - 2.05% 0.858% - 0.901% x x x x x x x x
Blood potassium decreased uncommon, 0.0702% - 1.13% 0% x
Anxiety 0.171% - 1.03% 0.36% - 1.07% x x
Gout 0.353% - 1.03% 0.18% x
Erectile dysfunction 0.353% - 2.05% 0% x
Viral infection 0.171% - 0.421% 1.07% x
Hyperbilirubinaemia 0% - 0.883% 0.36% x
Alopecia postmarketing x x x x x x x x
Anaphylactic shock postmarketing x x x x x x
Angioedema postmarketing x x x x x x x x
Asthenia postmarketing, uncommon x x x x x x x x
Hyperkalaemia postmarketing, rare x x x x x x x x
Hypotension rare, uncommon x x
Unspecified disorder of intestine postmarketing x x x
Renal failure acute postmarketing x x x x x x x x
Lethargy postmarketing x x
Mediastinal disorder postmarketing x x
Pruritus postmarketing x x x x x x x x
Rhabdomyolysis postmarketing x x x x x x x x
Urticaria postmarketing x x x x x x x x
Vomiting postmarketing, 0% - 3.23% 0% x x x x x x x x
Malnutrition postmarketing x x x x x x x x
Sprue postmarketing x x x
Malaise postmarketing x x
Myalgia postmarketing, uncommon x x x x x x x x
Blood creatinine increased postmarketing, 0.641% - 0.913% 1.07% x x x x x x x x
Hepatic enzyme increased postmarketing x x
Diabetic postmarketing x
Microalbuminuria postmarketing x
Asthenic conditions postmarketing x x
Agranulocytosis x
Anaemia x
Aplastic anaemia x
Haemolytic anaemia x
Anorexia x
Arrhythmia x
Mental disorder x x
Infection x x
Connective tissue disorder x x
Constipation x
Oedema x
Eosinophilia 0% 0% - 3.57% x
Toxic epidermal necrolysis x
Body temperature increased 0% - 3.23% 0% x x
Gastrointestinal disorder x x
Glycosuria x
Hyperhidrosis 0% - 3.45% 0% x
Hypokalaemia x
Hyponatraemia x
Jaundice x
Jaundice cholestatic x
Leukopenia x
Nephritis interstitial x
Nervous system disorder x x
Neutropenia x
Pancreatitis x
Pneumonia x
Renal failure x
Sialoadenitis x
Sleep disturbance x
Muscle spasms x
Thrombocytopenia x
Urinary tract disorder x
Angiopathy x
Vasculitis x
Agitation x
Blood urea increased uncommon, 0% 0% - 2.25% x x
Bone marrow depression x
Photosensitivity reaction x
Unspecified disorder of skin and subcutaneous tissue x
Lightheadedness x
Xanthopsia x
Cutaneous vasculitis x
Viral upper respiratory tract infection 0% 0% - 3.57% x
Electrolyte imbalance x
Vision blurred x
Gastric irritation x
Lupus erythematosus x
Transaminases increased x x x x x x
Respiratory distress x
Face oedema x x x x x x
Hypovolaemia x
Angiitis necrotising x
Infestation NOS x x
Blood and lymphatic system disorders x
Ear and labyrinth disorders x
Pharyngolaryngeal pain 0% - 3.23% 0% - 1.85% x
Bilirubin value increased x x x x x x
Pseudohyperkalaemia 0% - 1.08% 0% - 7.14% x
Rhinorrhoea 0% - 2.15% 0% x
Appetite absent x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

olmesartan

Side effects:43
Source:FDA Structured Product Label

OLMESARTAN

Side effects:43
Source:FDA Structured Product Label

OLMESARTAN

Side effects:43
Source:FDA Structured Product Label

OLMESARTAN

Side effects:45
Source:FDA Structured Product Label

OLMESARTAN

Side effects:45
Source:FDA Structured Product Label

OLMESARTAN

Side effects:47
Source:FDA Structured Product Label

OLMETEC / APPROVED

Side effects:83
Source:medicines.org.au

OLMETEC PLUS / APPROVED

Side effects:119
Source:medicines.org.au

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label